MARKET INDEX
KOSPI5,100.50▼ 3.59%
KOSDAQ665.65▼ 4.86%
S&P 5007,416.59▼ 1.92%
NASDAQ24,509.76▼ 2.49%
USD/KRW1,335.98▲ 0.16 (+0.01%)
WTI Crude$85.29▼ 0.50%
BTC/USD$64,674▼ 0.98%
KOSPI5,100.50▼ 3.59%
KOSDAQ665.65▼ 4.86%
S&P 5007,416.59▼ 1.92%
NASDAQ24,509.76▼ 2.49%
USD/KRW1,335.98▲ 0.16 (+0.01%)
WTI Crude$85.29▼ 0.50%
BTC/USD$64,674▼ 0.98%
헤더 좌
헤더 우
BREAKING
MARKET Times 공식 배너

Daewoong Pharmaceutical Reports Positive Phase 1 Interim Results for Autoimmune Drug Candidate Plodicitinib

Daewoong Pharmaceutical announced that its autoimmune drug candidate, Plodicitinib, achieved over 90% target occupancy for BTK and ITK in Phase 1 clinical trials.

Daewoong Pharmaceutical Reports Positive Phase 1 Interim Results for Autoimmune Drug Candidate Plodicitinib
MTIMES Archive / Photo

Single-ascending dose study on 44 healthy adults shows no serious adverse events. The oral candidate simultaneously targets JAK3, ITK, and BTK, with Phase 1 completion targeted for Q1 2027.

Daewoong Pharmaceutical announced on the 17th that the Phase 1 single-ascending dose (SAD) study for its autoimmune disease drug candidate, Plodicitinib (DWP212525), demonstrated a maximum target occupancy of over 90% for its primary targets, BTK and ITK. No serious adverse events were observed during the study period.

The findings were presented at the American College of Rheumatology (ACR) Convergence 2026 in Orlando, Florida. The results stem from the first-in-human Phase 1 trial involving 44 healthy adult participants. Target occupancy, a key indicator of how effectively a drug binds to its target protein, confirmed that Plodicitinib provides early pharmacodynamic evidence of its inhibitory action within the body.

Pharmacokinetic evaluations showed that systemic drug exposure increased in proportion to the dosage. In terms of safety, all treatment-emergent adverse events were mild, with no significant correlation between dosage increases and the frequency of adverse events.

Plodicitinib is an oral drug candidate under development for autoimmune and inflammatory diseases. Its mechanism involves the selective inhibition of JAK3, which regulates immune cell activity, and ITK and BTK, which are involved in the activation of T-cells and B-cells. Daewoong Pharmaceutical highlights the drug's ability to simultaneously inhibit these three targets to modulate immune responses, potentially expanding its application to conditions such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome.

The company has completed the SAD study and is currently conducting a multiple-ascending dose (MAD) study, with the goal of completing Phase 1 clinical trials by the first quarter of 2027.

Professor Lee Seung-hwan of the Department of Clinical Pharmacology at Seoul National University Hospital, who is overseeing the clinical trial, stated, "No significant safety issues, such as serious adverse events, were identified in the SAD study. Given the safety profile observed, we expect good tolerability in the ongoing MAD study."

Park Sung-soo, CEO of Daewoong Pharmaceutical, added, "The high target occupancy observed in this study is a significant early result for our continued clinical development. We will continue to secure clinical data through the ongoing MAD study and expand the development potential and global opportunities for Plodicitinib across various autoimmune diseases."

MARKET Times

MTIMES Global Editorial Statement

This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].

← More in CorporateBack to Top ↑

Related Market & Corporate Intelligence

Samsung and SK Hynix Face Antitrust Scrutiny in U.S. Over DRAM Supply StrategiesSamsung and SK Hynix Face Antitrust Scrutiny in U.S. Over DRAM Supply StrategiesGlobal Oil Market Divergence: Crude Surplus Meets Persistent Diesel TightnessGlobal Oil Market Divergence: Crude Surplus Meets Persistent Diesel TightnessFed Warns of Hidden Risks in Big Tech AI Investment SurgeFed Warns of Hidden Risks in Big Tech AI Investment SurgeEuropean Equities See Largest Inflow in Five Years as Investor Focus Shifts from US TechEuropean Equities See Largest Inflow in Five Years as Investor Focus Shifts from US Tech
HomeTOP10AlmatenPicksCorpAlgiten